SPXU vs XBI
ProShares UltraPro Short S&P500 vs SPDR S&P Biotech ETF
SPXU$36.42
ProShares UltraPro Short S&P500
3x inverse daily performance of the S&P 500.
Expense: 0.90%Yield: 6.85%
XBI$164.01
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.36%
Quick take
- • XBI has the lower expense ratio at 0.35% vs 0.90% for SPXU.
- • SPXU pays a higher dividend yield (6.85%).
Side-by-side metrics
| Metric | SPXU | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.90% | 0.35% |
Dividend yield Trailing 12-month yield. | 6.85% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $427M | $10.73B |
YTD return | -23.50% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | -2.75 | 1.10 |
P/E ratio | — | — |
Last price | $36.42 | $164.01 |
Inception | — | — |
Issuer | ProShares | State Street |
SPXU top holdings
Top holdings · SPXU
| IQMM | ProShares GENIUS Money Market ETF | 78.53% |
XBI top holdings
Top holdings · XBI
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
Sector breakdown · XBI
Financial Services0.5%
Healthcare99.5%
About SPXU
SPXU (ProShares UltraPro Short S&P500) is 3x inverse daily performance of the S&P 500. Managed by ProShares, the fund carries $427M in assets under management, an expense ratio of 0.90%, a dividend yield of 6.85%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 78.5% of the portfolio.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.